Business / Finance

RSS

Cardiome, AOP Orphan team up to commercialize AGGRASTAT in select European markets

Cardiome Pharma Corp. today announced an agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria, to commercialize AGGRASTAT® (tirofiban HCl) in selected European markets.

20 May 2014

BioLineRx announces financial results for Q1 2014, provides operational update

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for first quarter ended March 31, 2014.

20 May 2014

Proteo Biotech, BDC sign deal to develop orphan medicinal product Tiprelestat

Proteo Inc. announced today that its German subsidiary, Proteo Biotech AG, has entered into an agreement with the US company Biotech Development Corp. (BDC).

20 May 2014

Avita Health System to use NextGen solutions to track and enhance patient care

NextGen Healthcare Information Systems, LLC., a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, announced today an agreement with Avita Health System for the deployment of a range of NextGen® solutions across its extensive enterprise.

20 May 2014

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Orexo AB announces a new partnership between Orexo US, Inc. and inVentiv Health for the commercialization of Zubsolv in the US.

20 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo International plc announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones.

19 May 2014

KineMed extends collaboration with CHDI Foundation to track pathogenesis of Huntington's disease

KineMed, Inc. and CHDI Foundation, Inc. announced today an extension of their collaboration that uses KineMed's translational biomarker platform to characterize and track the pathogenesis of Huntington's disease (HD) and evaluate potentially therapeutic interventions.

19 May 2014

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the first quarter ended March 31, 2014.

17 May 2014

Abbott signs definitive agreement to acquire CFR Pharmaceuticals

Abbott today announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding Abbott's presence in fast-growing markets.

16 May 2014

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014.

16 May 2014

Kymab raises US$40 million in Series B financing

Kymab, a monoclonal antibody biopharmaceutical company, announced today it has successfully raised US$40 million in a Series B financing.

16 May 2014

Standard & Poor's upgrades HTA's investment grade credit rating to BBB

Healthcare Trust of America, Inc. (NYSE: HTA) announced today that Standard & Poor's ("S&P") has upgraded HTA's investment grade credit rating to BBB, with a stable outlook.

16 May 2014

Agfa HealthCare launches ICIS for mobile and web capture at SIIM 2014, extending the "Evolution of Visual Healthcare" to smart phones and tablets

Extending the "Evolution of Visual Healthcare" to mobile devices, Agfa HealthCare announced today the launch of its new web-enabled mobile image management technology that brings the power of ICIS to iPhones, iPads, Web, and Android mobile digital devices.

15 May 2014

Actavis reaches agreement to continue supplying authorized generic version of JPI's Concerta

Actavis plc today announced that it has reached an agreement with Janssen Pharmaceuticals, Inc. to continue supplying the authorized generic version of JPI's Concerta (methylphenidate hydrochloride extended-release tablets).

15 May 2014

Cord Blood America's total revenue decreases 3% to $1.42 million in Q1 2014

Cord Blood America, Inc. today announced financial results for the quarter ended March 31, 2014.

15 May 2014

Inspire Medical Systems completes $40 million Series E financing

Inspire Medical Systems, Inc. announced today that it has completed a Series E financing of $40 million. The financing round was strategically timed to coincide with the commercial launch of the Inspire Upper Airway Stimulation (UAS) therapy in the United States.

15 May 2014

ERBA Diagnostics reports decrease in Q1 2014 net revenues

ERBA Diagnostics, Inc., a fully integrated in vitro diagnostics company, reported its financial results for the three months ended March 31, 2014.

15 May 2014

Boston Scientific to acquire Bayer’s Interventional Division

In a move to expand significantly its portfolio of leading solutions for peripheral interventions, Boston Scientific Corporation has entered into a definitive agreement to acquire the Interventional Division of Bayer AG for $415 million in cash, including fees for transitional services.

15 May 2014

Eleven Biotherapeutics reports financial results and operational highlights for Q1 2014

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results and operational highlights for the quarter ended March 31, 2014.

15 May 2014